Researchers tackling biggest health crises say open-source collaboration is now ‘fundamental’

Researchers tackling biggest health crises say open-source collaboration is now ‘fundamental’

75% of 500 global researchers are collaborating on health research projects including oncology and infectious disease monitoring

LONDON, June 2023: As the UK Health Security Agency announces a plan for a “genomics transformation”, new data has revealed that nearly three quarters (72%) of research scientists believe open-source collaboration and workflow management is now “fundamental” to the work they do.

The data published by Seqera Labs, the leading provider of secure data orchestration software, brings together the views of 500 researchers and scientists who use open-source scientific workflow platforms for their work. Such systems are used by researchers to standardize the way data is analysed, reduce duplication and provide the infrastructure for high level projects both within their organizations and externally in genomics, metagenomics, and transcriptomics.

The study found that open-source workflow platforms are currently being utilized across all continents, with two fifths (41%) noting the value for cross-organization collaboration and a third (32%) highlighting the benefits in international collaboration more broadly. With global scientific knowledge and resources spread across the world, over two fifths (41%) said community adoption of a workflow system was very important to the future of their research. One in three (34%) noted the financial savings that open-source scientific workflows had brought them as significant for their research.

Harshil Patel, Head of Scientific Development, Seqera Labs comments: “Significant improvements in the ability for data orchestration tools to manage and organize large volumes of data empowered nations to monitor the spread of Covid-19 and continue to operate at the forefront of the world’s defences against the likes of influenza, RSV and Avian Flu. These tools are operating on the precipice of scientific discovery and are acting as the first line of defence against pandemic threats. Improved efficiency and scalability of research infrastructure is now fundamental for ongoing scientific research and future breakthroughs as they are no longer impeded by cost or capacity restraints when it comes to the pipelines used.”

As breakthroughs in personalized medicines and gene therapies create the prospect of ever-more sophisticated treatments for patients, the scientific infrastructure behind such research is improving alongside it. One such area is the uptake of public cloud-based providers which brings benefits in terms of project scalability. Over two fifths (42%) of researchers said they use public cloud, up 20% on the year before. Among private sector organizations, this figure is even higher, with 80% of organizations using public cloud.

The preferred provider amongst those surveyed was by far Amazon Web Services, with 49% saying it would be their chosen public cloud were they to migrate. 12% said they would opt for Google cloud and 8% said Azure.

Evan Floden, Founder and CEO of Seqera Labs comments: “As the use of cloud computing continues to play a foundational role in bioinformatics research, there remains a need for cost-effective and scalable ways to store and process large volumes of sequencing data. Meeting this technical challenge has been crucial for the progression of precision medicines and will only become more important as these orchestration tools are further embedded into our global research structures.  The dawn of the collaborative approach to scientific research, which utilizes scalable data orchestration tools, has led to new therapies, personalized treatments, and a shift in terms of what is possible for scientists to achieve.”

About Seqera Labs

Seqera Labs is the leading provider of secure data orchestration software in the life sciences sector. It reduces the cost and complexity of working with data en masse, providing the tools to drive innovations in genomics, global health and beyond. ​

Founded in 2018 by Evan Floden and Paolo Di Tommaso, Seqera Labs is trusted by organizations including AstraZeneca, Roche, Johnson & Johnson, and Janssen Pharmaceuticals. It was the recipient of several grants from the Chan Zuckerberg Initiative and in 2022, announced €22m in Series A funding with Addition as its lead investor.​

The creator of open-source Nextflow and Tower, it has helped some of the largest pharmaceutical, life sciences and biotech companies worldwide to transform their approach to data analysis and orchestration, allowing them to bring therapeutics that improve patients’ lives to market faster. Championing ‘open science’ , its experts also act as the curators of data made public for collaboration from the wider scientific community, with over 120 pipelines available for use by its community of over 16,000 researchers.​

For more information visit seqera.io or follow the company at @Seqeralabs